VTX-801_CLN_001 A Phase I/II, Multicenter, Non-randomized, Open Label, Adaptive Design, 5-year Follow up, Single Dose-escalation Study of VTX-801 in Adult Patients with Wilson’s Disease.

NCT04537377

A Phase I/II, Multicenter, Non-randomized, Open Label, Adaptive Design, 5-year Follow up, Single Dose-escalation Study of VTX-801 in Adult Patients with Wilson’s Disease.

Associated Conditions

Wilsons Disease

Principal Investigator

Sponsor

Vivet Therapeutics, SAS

This Clinical Trial is being conducted to assess the effects of an experimental drug (study drug) called VTX-801 intended to treat Wilson’s Disease (WD). The purpose of this clinical study is to assess what effects, good and bad, VTX-801 may have on you and your WD and to find the most appropriate dose for future clinical trial(s).

This study is currently enrolling.